Respiratory Research (Feb 2023)

Interstitial lung abnormalities in a large clinical lung cancer screening cohort: association with mortality and ILD diagnosis

  • Avignat S. Patel,
  • Ezra Miller,
  • Shawn M. Regis,
  • Gary M. Hunninghake,
  • Lori Lyn Price,
  • Melissa Gawlik,
  • Andrea B. McKee,
  • Kimberly M. Rieger-Christ,
  • Victor Pinto-Plata,
  • Timothy N. Liesching,
  • Christoph Wald,
  • Jeffrey Hashim,
  • Brady J. McKee,
  • Lee Gazourian

DOI
https://doi.org/10.1186/s12931-023-02359-9
Journal volume & issue
Vol. 24, no. 1
pp. 1 – 8

Abstract

Read online

Abstract Background Interstitial lung abnormalities (ILA) are CT findings suggestive of interstitial lung disease in individuals without a prior diagnosis or suspicion of ILD. Previous studies have demonstrated that ILA are associated with clinically significant outcomes including mortality. The aim of this study was to determine the prevalence of ILA in a large CT lung cancer screening program and the association with clinically significant outcomes including mortality, hospitalizations, cancer and ILD diagnosis. Methods This was a retrospective study of individuals enrolled in a CT lung cancer screening program from 2012 to 2014. Baseline and longitudinal CT scans were scored for ILA per Fleischner Society guidelines. The primary analyses examined the association between baseline ILA and mortality, all-cause hospitalization, and incidence of lung cancer. Kaplan–Meier plots were generated to visualize the associations between ILA and lung cancer and all-cause mortality. Cox regression proportional hazards models were used to test for this association in both univariate and multivariable models. Results 1699 subjects met inclusion criteria. 41 (2.4%) had ILA and 101 (5.9%) had indeterminate ILA on baseline CTs. ILD was diagnosed in 10 (24.4%) of 41 with ILA on baseline CT with a mean time from baseline CT to diagnosis of 4.47 ± 2.72 years. On multivariable modeling, the presence of ILA remained a significant predictor of death, HR 3.87 (2.07, 7.21; p < 0.001) when adjusted for age, sex, BMI, pack years and active smoking, but not of lung cancer and all-cause hospital admission. Approximately 50% with baseline ILA had progression on the longitudinal scan. Conclusions ILA identified on baseline lung cancer screening exams are associated with all-cause mortality. In addition, a significant proportion of patients with ILA are subsequently diagnosed with ILD and have CT progression on longitudinal scans. Trial registration number: ClinicalTrials.gov; No.: NCT04503044.

Keywords